ANNXライブシグナル | Getagraph.comで利益を最大化

買う 99959 min ago

@ $5.26

発行日: 15 2月 2024 @ 04:48

リターン: -15.51%

前回のシグナル: 2月 14 - 23:31

前回のシグナル: 売る

リターン: 2.24 %

Live Chart Being Loaded With Signals

Commentary (24 4月 2024 @ 05:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
本日の出来高	801 528
平均出来高	1.58M
時価総額	466.58M
EPS	$0 ( 2024-04-01 )
次の収益日	( $-0.440 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.51
ATR14	$0.0110 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock
2024-02-16	Artis Dean Richard	Buy	160 000	Stock Option (Right to Buy)

INSIDER POWER
80.78
Last 94 transactions
Buy: 9 088 380 \| Sell: 879 119

ボリューム相関

長: -0.46 (neutral)

短: -0.63 (weak negative)

Signal:(51.222) Neutral

Annexon, Inc. 相関

10 最も正の相関
RMRM	0.934
GTHX	0.93
STKL	0.913
NUTX	0.91
EYE	0.91
DXCM	0.91
SDG	0.909
EAR	0.908
SVOK	0.907
RRGB	0.906

10 最も負の相関
HDSN	-0.916
LCA	-0.9
MDWT	-0.896
NVCN	-0.89
SENEA	-0.885
OHAA	-0.882
HNRG	-0.879
ROKU	-0.878
IGTA	-0.877
FCBP	-0.877

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Annexon, Inc. 相関 - 通貨/商品

-0.43
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.65
( weak negative )

0.00
( neutral )

0.77
( moderate )

Annexon, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.27M (0.00 %)
EPS:	$-1.770

Q4	2023
収益:	$0
総利益:	$-834 000 (0.00 %)
EPS:	$-0.360

Q3	2023
収益:	$0
総利益:	$-823 000 (0.00 %)
EPS:	$-0.430

Q2	2023
収益:	$0
総利益:	$-810 000 (0.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.